Cassava Sciences: Likely Potential Opportunity From Phase 3 Readout (NASDAQ:SAVA) seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.
New data from TRAILBLAZER-ALZ 2 show robust amyloid clearance with donanemab in APOE4 carriers and noncarriers, mitigating the risk of disease progression and dependency.
An experimental tau aggregation inhibitor significantly reduced tau, an established biomarker of neurodegeneration, which correlated with changes in cognitive test scores.
Alzheimer s cognitive decline slows significantly with donanemab alzheimersnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from alzheimersnewstoday.com Daily Mail and Mail on Sunday newspapers.
The phase 3 drug trial from Eli Lilly and Company indicated significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer's.